Ghulam Md. Ashraf*, Badrah S. Alghamdi, Fahad S. Alshehri, Mohammad Z. Alam, Haythum O. Tayeb and Frank I. Tarazi Pages 53 - 59 ( 7 )
Aim: The primary aim of this study was to standardize the correlated effective dosage of the antidiabetic drug empagliflozin (EMPA) and the antipsychotic drug olanzapine (Ola).
Background: Atypical antipsychotics are associated with BWG and metabolic disturbances for which many approaches have been used to minimize these issues, including antidiabetic drugs. The antidiabetic drugs have been quite effective in reversing BWG induced by the administration of antipsychotic drugs in patients who have psychosis, schizophrenia and bipolar disorder.
Objective: The objective of this study was to standardize the correlated effective dosage of EMPA and Ola.
Methods: The study was carried out for 28 days to represent the chronic effect of Ola on female Wistar rats. Rats were divided into three groups based on the dose they received: control (vehicle), Ola-4 and Ola-8 (4 and 8 mg/kg/OD, respectively), and EMPA-10 and EMPA-20 (10 and 20 mg/kg/OD, respectively).
Results: Both doses of Ola produced a significant increase in the percentage of BWG, however, Ola-4 produced a higher BWG. Also, both the doses of EMPA were able to reverse the effect of Ola-induced BWG; however, EMPA-20 produced a higher reversal in BWG and normalized the rat's body weight.
Conclusion: We conclude that Ola-4 and EMPA-20 were the most effective dosage for experimental purposes in female Wistar rats. The findings of this study standardized the effective correlated dosage of olanzapine and empagliflozin in female Wistar rats that will help understand the underlying molecular and behavioral mechanisms.
Antidiabetics, antipsychotics, body weight gain, empagliflozin, female wistar rats, olanzapine.
Pre-Clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Pre-Clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Pre-Clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Division of Neurology, Department of Internal Medicine, King Abdulaziz University, Jeddah, Department of Psychiatry and Neurology, Harvard Medical School and McLean Hospital, Belmont, MA 02478